Daniel Speidel Email & Phone Number

Hamburg, Hh, De

Breakpoint Therapeutics is a spin-off of Evotec SE dedicated to the discovery of anti-cancer drugs that target the DNA Damage Response (#DDR) in cancer cells. The new company will advance drug discovery programs initiated internally at Evotec and develop first-in-class oncology drugs that interfere with DNA-repair and replication stress tolerance pathways. Our aim is to develop drugs that succeed and complement PARP-inhibitors and facilitate the cure of therapy-resistant cancers.Breakpoint Therapeutics is backed by a consortium of renowned life science investors: Medicxi, Taiho Ventures, Evotec and BVF Partners.www.breakpointtx.com

I have advised a number of organisations, mainly in the medicine/biotech/research and not-for-profit sectors, and helped with specific tasks. My former clients include also two market-leading global players. Topics have included strategy, business development, growth/merger/acquisitions, recruiting and event management.

Hamburg, De

My main task was to establish an Evotec Innovate project as a virtual spin out company. This included development and implementation of a commercial and scientific strategy. In addition, I established partnerships with co-investors/VCs and academic experts to help us succeed. In June 2019, these activities led to formation of Breakpoint Therapeutics GmbH - the spin-off company of Evotec that I was entrusted to lead as Managing Director.

The University Of Sydney, New South Wales, Au

- Supervision of postgraduate research students

Westmead, Nsw, Au

Experimental cancer research.My research explored how normal and cancer cells respond to radiation and chemotherapeutic agents. The overall aims were to understand better the molecular basis of tumour suppression and improve cancer therapy. My activities included:- Management and supervision of independent cancer research program and team - Budget responsibility - Dissemination of results through peer reviewed publications and presentations at international conferences and invited seminars- Acquisition of funding through grant applications in competitive funding schemes- Collaboration with leading clinical oncologists - Expert assessment and evaluation of scientific research proposals (grants & fellowship applications) and manuscripts for leading international research organisations/ journals- Co-organisation of national cancer research conferences- Editor of international cancer research journals- Mentor of students, postdoctoral fellows and junior research staffTopics: cancer, therapy response, personalised medicine, DNA damage responses, p53, mechanisms of tumour suppression and therapy response, biomarkers predicting cancer therapy resistance, radiation biology

Hamburg, De

Experimental cancer research in the laboratories of Prof. Dr. Wolfgang Deppert (Dept. of Tumor Virology) and Dr. Carol Stocking (Molecular Pathology Group). My research elucidated the function of the tumour suppressor gene p53 and identified the Gadd45beta gene as a novel regulator associated with therapy resistance in blood cancer.

Hamburg, De

Experimental cancer research in the laboratory of Professor Wolfgang Deppert (Dept. of Tumor Virology).My research focused on the tumour suppressor protein p53 and the question as to how p53 promotes cell death or survival of cells that were treated with DNA damaging agents.My publication in the journal Oncogene, describing the results of my PhD thesis, was awarded the renowned Konjetzny Award for Cancer Research.

Us

I analysed the recruitment and selection processes for new hires at McKinsey and recommended substantial changes. All of my major recommendations have been implemented and changed the strategy by which the German Office of McKinsey recruits new consultants - up to now.

I advised the managing partners of this newly founded biotech start-up on matters of strategic relevance. In particular, I evaluated the strategic fit and benefits of a plan to establish a new oncological business unit and thereby expand the company. Following my recommendation, the management of Mice & More decided to not pursue this expansion.

Us

Strategic business consulting.I worked on a growth study for a client in the processing industry and helped to prepare a successful acquisition.

Dr. Rer. Nat (Phd), Cancer Research

Diplom-Biochemiker, Biochemistry

Studium Generale